Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
JAMA Cardiology|February 28, 2017
The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers: Findings From the HCMNet StudyCarolyn Y Ho, Sharlene M Day, Steven D Colan, et al.
Circulation Research|March 20, 2013
Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutationsVasco Sequeira, Paul J M Wijnker, Louise L A M Nijenkamp, et al.
JAMA Cardiology|March 5, 2025
Valsartan and Cardiac Remodeling in Early-Stage Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial Cardiac Magnetic Resonance SubstudyJohn W Ostrominski, Brian L Claggett, Michael Jerosch-Herold, et al.
Circulation. Heart Failure|May 9, 2025
Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical TrialConstantin-Cristian Topriceanu, Christoffer Rasmus Vissing, Anna Axelsson Raja, et al.
Cardiology in the Young|September 18, 2015
Summary of the 2015 International Paediatric Heart Failure Summit of Johns Hopkins All Children's Heart InstituteJeffrey P Jacobs, James A Quintessenza, Tom R Karl, et al.
JAMA Cardiology|September 6, 2023
Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical TrialChristoffer Rasmus Vissing, Anna Axelsson Raja, Sharlene M Day, et al.
Circulation. Heart Failure|December 10, 2019
Baseline Characteristics of the VANISH CohortAnna Axelsson Raja, Ling Shi, Sharlene M Day, et al.
Nature Medicine|September 24, 2021
Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trialCarolyn Y Ho, Sharlene M Day, Anna Axelsson, et al.
European Heart Journal|August 12, 2025
Titin-related familial dilated cardiomyopathy: factors associated with disease onsetRenee Johnson, Robert A Fletcher, Stacey Peters, et al.
Pageof 6